Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| NB N-Zyme BiomedicalCompany profile Developing first-in-class therapies targeting pepsin for reflux disease Developing first-in-class therapies targeting pepsin for reflux disease | $4.6M | Series A | Biotech | United States | Investors Undisclosed | |
| RN Rege Nephro CoCompany profile Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options | $10.6M | Series CSeries C+ | Biotech | Japan | Investors | |
| ET Estrigenix TherapeuticsCompany profile Developing selective estrogen receptor-beta therapeutics for women's health and neurodegenerative diseases Developing selective estrogen receptor-beta therapeutics for women's health and neurodegenerative diseases | $2M | Seed | Biotech | United States | Investors | |
| BP Brenus PharmaCompany profile Develops an off-the-shelf in vivo immunotherapy platform for solid tumors Develops an off-the-shelf in vivo immunotherapy platform for solid tumors | €11M | Series A | Biotech | France | Investors | |
| SB Sightera BiosciencesCompany profile Belgian techbio company using generative AI to develop novel small-molecule therapies Belgian techbio company using generative AI to develop novel small-molecule therapies | €3M | Pre-SeedPre-seed | Biotech | Belgium | Investors | |
| TB Trellis BioscienceCompany profile Developing native human monoclonal antibodies to treat intractable infectious diseases Developing native human monoclonal antibodies to treat intractable infectious diseases | $9M | Series CSeries C+ | Biotech | United States | Investors | |
| A AdvanCellCompany profile AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing. AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing. | $315M | Series DSeries C+ | Biotech | Australia | Investors AbingworthAlly Bridge Group +17Alpha WaveBain Capital Life SciencesBrandon CapitalCatalio Capital ManagementEli Lilly and CompanyEventide Asset ManagementFidelity Management & Research CompanyMorningsidePiper HeartlandProto AxiomSanofi VenturesSV Health InvestorsSymBiosisTenmileTime BioVenturesT. Rowe Price AssociatesVelosity Capital | |
| N NousCompany profile Develops functional ingredients for the food, beverage and nutraceutical industries Develops functional ingredients for the food, beverage and nutraceutical industries | €2.3M | Seed | Biotech, Foodtech | Italy | Investors | |
| AH Auxilium HealthCompany profile Auxilium Health makes bioaerogel biomaterials that block bacteria and aid tissue regeneration Auxilium Health makes bioaerogel biomaterials that block bacteria and aid tissue regeneration | $3.4M | Seed | Biotech, Healthtech | United States | Investors Undisclosed | |
| DT Draig Therapeutics develops neuropsychiatric medicines. | $65M | Series B | Biotech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.